Brain biomarkers were long hard to pin down. See how new Parkinson's and Alzheimer's biomarkers are changing that.

Discover biotech and big pharma’s emerging interest in developing macrocyclic drugs for cardiometabolic diseases.

PMOS, formerly PCOS, still has no approved dedicated drug. Discover the new PMOS treatments in development, from GLP-1s to ...

Learn how to choose and integrate automated liquid handling solutions while overcoming challenges and supporting flexible lab ...

Over the past decade, a succession of new GvHD treatments targeting different components of the immune response have been ...

Find out what came out of the World Conference on Lung Cancer (WCLC) 2026, from late-stage successes and failures to earlier-stage promise.

Discover how GLP-1 drugs are being studied for potential new indications, from autoimmune diseases and addiction to Parkinson’s and MASH.

Delve into the AstraZeneca pipeline strategy in 2026 as its oncology franchise keeps growing and it invests in diversification.

Candel Therapeutics is focused on the development of off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight ...

For a long time, neurological drug development has largely focused on the cells that ultimately die or malfunction. Alzheimer’s researchers chased amyloid and tau. Parkinson’s drug development ...